 A productivity crisis is happening in the pharmaceutical research and development (R&D) industry. Technological change is disrupting the status quo and will drive change in all aspects of the industry, which is exhibiting several characteristics of maturing industries. The lack of results suggests that the current approach to small molecule R&D may be approaching exhaustion. Concurrently, the industry’s operating landscape is fundamentally changing, and this will force significant changes among existing pharmaceutical companies. It is anticipated that the future of the pharmaceutical industry will include New PharmCos that are explicitly configured to succeed in this new fast-paced environment. These New PharmCos will be a fundamental threat to existing players, which will need to realign their R&D methods to be able to adapt in the changing landscape. Read The Changing Face of R&D in the Future Pharmaceutical Landscape to learn more about the emerging paradigm in drug development. Related Content:
Press Release: The Changing Face of R&D in the Future Pharmaceutical Landscape
Report: Managing Pathways to Convergence in the Life Sciences Industry
Report: The Future of the Life Sciences Industry: Strategies for Success in 2015
|